Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

REPLICA-EPICA 18 Registry: Using IVL in Calcified Coronary Lesions

The presence of calcification in the coronary arteries (CAC) remains the main challenge in the percutaneous treatment of these lesions. Various studies have demonstrated the association of CAC with unfavorable long-term outcomes. Intravascular lithotripsy (IVL) has emerged as an effective tool for fracturing calcified plaques. Studies evaluating this strategy have shown high device success rates, with good clinical and angiographic outcomes. These, however, have not been randomized trials.

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

The aim of this prospective, multicenter study was to assess the effectiveness and safety of IVL in calcified lesions in a cohort of consecutive real-world patients.

The primary efficacy endpoint (PEP) was procedural success, defined as successful percutaneous coronary intervention (PCI) with residual stenosis <20% and no in-hospital complications (cardiac death, acute myocardial infarction [AMI], or need for target vessel revascularization [TVR]). The secondary safety endpoint (SEP) was the rate of major adverse cardiac events (MACE), defined as death, AMI, or TVR.

The study included a total of 426 patients with 456 lesions. The mean age was 73 years, and most patients were men. The most frequent clinical presentation was acute coronary syndrome (ACS), in 63% of cases. Most patients had good ventricular function (LVEF >50%), and transradial access was the most frequently used access (76%). The most affected coronary artery was the left anterior descending artery (44%), followed by the right coronary artery (31%), the circumflex artery (12%), and the left main coronary artery (11%).

Read also: Third Generation Balloon-Expandable and Self-Expanding Valves: TAVR Meta- Analysis.

Regarding the efficacy PEP, it was achieved in 66% of the patients, with similar rates between ACS patients (65%) and patients with chronic coronary syndromes (CCS) (68%). There were no significant differences in angiographic success after IVL between these two patient groups. As for the safety SEP, the 30-day MACE rate was 3%: it was 1% in CCS patients and 5% in ACS patients (p=0.073).

Conclusion

The use of IVL proved to be a feasible and safe procedure in a real-world patient population, effectively facilitating stent implantation in severely calcified lesions. ACS patients showed similar angiographic success rates but tended to have higher 30-day MACE rates compared with CCS patients. Long-term studies are needed to evaluate the clinical benefits associated with this therapeutic tool.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: A Prospective, Multicenter, Real-World Registry of Coronary Lithotripsy in Calcified Coronary Arteries The REPLICA-EPIC18 Study.

Reference: Oriol Rodriguez-Leor, MD, PHD et al J Am Coll Cardiol Intv 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...